Asset Details
Do you wish to reserve the book?
Whole-body organ-level and kidney micro-dosimetric evaluations of super(64)Cu-loaded HER2/ErbB2-targeted liposomal doxorubicin ( super(64)Cu-MM-302) in rodents and primates
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Whole-body organ-level and kidney micro-dosimetric evaluations of super(64)Cu-loaded HER2/ErbB2-targeted liposomal doxorubicin ( super(64)Cu-MM-302) in rodents and primates
Do you wish to request the book?
Whole-body organ-level and kidney micro-dosimetric evaluations of super(64)Cu-loaded HER2/ErbB2-targeted liposomal doxorubicin ( super(64)Cu-MM-302) in rodents and primates
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Whole-body organ-level and kidney micro-dosimetric evaluations of super(64)Cu-loaded HER2/ErbB2-targeted liposomal doxorubicin ( super(64)Cu-MM-302) in rodents and primates
2015
Overview
Features of the tumor microenvironment influence the efficacy of cancer nanotherapeutics. The ability to directly radiolabel nanotherapeutics offers a valuable translational tool to obtain biodistribution and tumor deposition data, testing the hypothesis that the extent of delivery predicts therapeutic outcome. In support of a first in-human clinical trial with super(64)Cu-labeled HER2-targeted liposomal doxorubicin ( super(64)Cu-MM-302), a preclinical dosimetric analysis was performed. Whole-body biodistribution and pharmacokinetic data were obtained in mice that received super(64)Cu-MM-302 and used to estimate absorbed radiation doses in normal human organs. PET/CT imaging revealed non-uniform distribution of super(64)Cu signal in mouse kidneys. Kidney micro-dosimetry analysis was performed in mice and squirrel monkeys, using a physiologically based pharmacokinetic model to estimate the full dynamics of the super(64)Cu signal in monkeys. Organ-level dosimetric analysis of mice receiving super(64)Cu-MM-302 indicated that the heart was the organ receiving the highest radiation absorbed dose, due to extended liposomal circulation. However, PET/CT imaging indicated that super(64)Cu-MM-302 administration resulted in heterogeneous exposure in the kidney, with a focus of super(64)Cu activity in the renal pelvis. This result was reproduced in primates. Kidney micro-dosimetry analysis illustrated that the renal pelvis was the maximum exposed tissue in mice and squirrel monkeys, due to the highly concentrated signal within the small renal pelvis surface area. This study was used to select a starting clinical radiation dose of super(64)Cu-MM-302 for PET/CT in patients with advanced HER2-positive breast cancer. Organ-level dosimetry and kidney micro-dosimetry results predicted that a radiation dose of 400 MBq of super(64)Cu-MM-302 should be acceptable in patients.
Subject
We currently cannot retrieve any items related to this title. Kindly check back at a later time.